Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

Tito Fojo(James J. Peters VA Medical Center), Andrew W. Lo(Massachusetts Institute of Technology), Sham Mailankody(Memorial Sloan Kettering Cancer Center)
JAMA Otolaryngology–Head & Neck Surgery
July 28, 2014
10.1001/jamaoto.2014.1570
Cited by 301

Related Papers

Combination Chemotherapy in Advanced Adrenocortical Carcinoma
|New England Journal of Medicine|2012|863
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
|JAMA Internal Medicine|2017|497
The high price of anticancer drugs: origins, implications, barriers, solutions
|Nature Reviews Clinical Oncology|2017|430
GPRC5D-Targeted CAR T Cells for Myeloma
|New England Journal of Medicine|2022|383
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
|JAMA Oncology|2015|309